Skip to main content

Table 2 Details of NSAIDs/low-dose aspirin

From: Non-steroidal anti-inflammatory drug-induced enteropathy as a major risk factor for small bowel bleeding: a retrospective study

 

N = 37 (100%)

(NSAID = 17/Low-dose aspirin = 21)a

Indication

 Coronary artery disease

11 (29.7)

 Other cardiovascular disease

9 (24.3)

 Musculoskeletal disease

15 (40.5)

 Unknown

3 (8.1)

Duration

  < 1 month

2 (5.4)

 1–6 months

11 (29.7)

  > 6 months

22 (59.5)

 Unknown

2 (5.4)

Concurrent medication

 Clopidogrel

6 (16.2)

 Warfarin/NOAC

7 (18.9)

 Other anti-platelet agent

3 (8.1)

 None

21 (56.8)

Site of bleeding

 Small bowel

33 (89.2)

 Stomach

2 (5.4)

 Undetermined

2 (5.4)

Etiology of small bowel bleedingb

 NSAID-induced enteropathy

25 (75.8)

 Angioectasia

7 (21.2)

 Others

1 (3.0)

Initial management of NSAID-induced enteropathyc

 Discontinue NSAID/low-dose aspirin

20 (80.0)

 Continue NSAID/low-dose aspirin

2 (8.0)

+ Mucosal protective agentd

 Unknown

3 (12.0)

  1. a One patient had a history of both NSAID and low dose aspirin
  2. b The denominator is 33 patients with confirmed small bowel bleeding on capsule endoscopy
  3. c The denominator is 25 patients with small bowel bleeding associated with NSAID/low-dose aspirin
  4. d Mucosal protective agent indicates rebamipide, sucralfate, or sodium alginate
  5. NSAID, nonsteroidal anti-inflammatory drug; NOAC, non-vitamin K antagonist oral anticoagulant